From - A Hematology Oncology Wiki
Jump to: navigation, search

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

1 regimens on this page
1 variants on this page

Note: this is a new type of page for, as all other regimen pages (except for cancer of unknown primary) are tissue-specific. The initial drug with tissue-agnostic approval is for patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options.

Pembrolizumab monotherapy


Study Evidence
Le et al. 2016 (KEYNOTE-164) Phase II

Note: this is the FDA-approved pembrolizumab dose and schedule based on a pooled analysis of 5 non-randomized trials. This is one representative trial.


21-day cycle for up to 2 years


  1. Abstract: Dung T. Le, Takayuki Yoshino, Dirk J├Ąger, Thierry Andre, Johanna C. Bendell, Ruixue Wang... SoonMo Peter Kang, Minori Koshiji, Luis A. Diaz. KEYNOTE-164: Phase II study of pembrolizumab (MK-3475) for patients with previously treated, microsatellite instability-high advanced colorectal carcinoma. J Clin Oncol 2016 abstract TPS787 and abstract TPS3631; NCT02460198 at